| Not Yet Recruiting | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Tr NCT07444489 | Biogen | Phase 3 |
| Active Not Recruiting | TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlati NCT07316829 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation NCT06744647 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants NCT06685757 | Biogen | Phase 3 |
| Withdrawn | Isatuximab in Lung Transplant Recipients NCT05862766 | NYU Langone Health | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney T NCT06503731 | argenx | Phase 2 |
| Recruiting | A Prospective Randomized Trial of ECP in Subclinical AMR NCT06112951 | Medical University of Vienna | N/A |
| Unknown | The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation NCT05913596 | First Affiliated Hospital of Zhejiang University | N/A |
| Recruiting | TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients NCT04561986 | Vastra Gotaland Region | Phase 3 |
| Unknown | Incidence, Course and Outcome of ABMR in Kidney Transplantation NCT05140018 | University Medical Center Groningen | — |
| Completed | Felzartamab in Late Antibody-Mediated Rejection NCT05021484 | Farsad Eskandary | Phase 2 |
| Recruiting | Biorepository and Registry for Plasma Exchange Patients NCT05004493 | Charles M Knudson | — |
| Completed | Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection NCT04897438 | Charite University, Berlin, Germany | N/A |
| Active Not Recruiting | MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT) NCT05184426 | Juan Francisco Delgado Jimenez | — |
| Unknown | DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients NCT04368962 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Completed | Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT NCT04541914 | Seoul National University Hospital | N/A |
| Completed | Desensitization in Kidney Allograft Using Daratumumab NCT04204980 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation NCT03388008 | Washington University School of Medicine | Phase 2 |
| Completed | Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR NCT03737136 | Shahid Beheshti University of Medical Sciences | N/A |
| Terminated | Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients NCT03744910 | CSL Behring | Phase 3 |
| Completed | Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection NCT04367610 | Istanbul University | — |
| Unknown | DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection NCT03702257 | University Hospital, Strasbourg, France | N/A |
| Completed | Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation NCT04026087 | University Hospital, Montpellier | — |
| Terminated | Transplant Antibody-Mediated Rejection: Guiding Effective Treatments NCT03994783 | Imperial College London | Phase 3 |
| Withdrawn | Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization NCT03805178 | Duke University | Phase 2 |
| Unknown | Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration Plas NCT03436134 | University Hospital, Grenoble | N/A |
| Completed | Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation NCT03474536 | University Hospital, Bordeaux | — |
| Active Not Recruiting | Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant NCT03380962 | Stanley Jordan, MD | Phase 1 / Phase 2 |
| Completed | Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant NCT03380377 | Stanley Jordan, MD | Phase 1 / Phase 2 |
| Unknown | Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response NCT03430414 | Thomas Mueller | — |
| Completed | A Pilot Trial of Clazakizumab in Late ABMR NCT03444103 | Medical University of Vienna | Phase 2 |
| Terminated | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatm NCT03221842 | CSL Behring | Phase 3 |
| Active Not Recruiting | VIRTUUS Children's Study NCT03719339 | Children's Hospital of Philadelphia | — |
| Completed | HPA Antibodies and the Distribution of Antigen and Antibodies NCT03408158 | Guangzhou First People's Hospital | N/A |
| Terminated | Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study NCT02120482 | Medical University of Vienna | N/A |
| Withdrawn | Belatacept in Kidney Transplantation of Moderately Sensitized Patients NCT02130817 | University of Wisconsin, Madison | Phase 4 |
| Completed | Bortezomib in Late Antibody-mediated Kidney Transplant Rejection NCT01873157 | Medical University of Vienna | Phase 2 |
| Terminated | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation NCT01895127 | Brigham and Women's Hospital | Phase 2 |
| Terminated | Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants NCT01630538 | University of Manitoba | Phase 2 |
| Completed | The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation NCT02013037 | Cedars-Sinai Medical Center | Phase 3 |
| Terminated | Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation NCT01848301 | Gladwin, Mark, MD | Phase 1 |
| Terminated | Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensit NCT01399593 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange NCT02533596 | Hannover Medical School | — |
| Unknown | Antibodies and Liver Retransplantation NCT03815864 | London Health Sciences Centre | — |